Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Chinese Subjects with Advanced Solid Tumors
NCT03523390Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab in solid tumor (4 arms), sponsored by Merck KGaA. Primary endpoints: Dose-limiting Toxicities, Area Under the Serum Concentration Time Curve From Time Zero to Last Quantifiable Concentration at Day 1 and 8 more. Started Apr 2018; status: completed.
02
Drugs
avelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03523390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523390.